DEEP STATES ASSOCIATED WITH PLATINUM DECORATED STACKING-FAULTS IN SILICON by Lahiji, G, Peaker, A, Hamilton, B

Automobile exhaust catalysis at the atomic scale: atom-probe investigations on platinum alloys by Bagot, P, Cerezo, A, Smith, G, de Bocarme, T, Godfrey, T

TEM investigations of industrial platinum on graphite catalyst systems: Image processing and particle morphology by Weller, S, Nellist, P, Gillies, J, Palmer, R

“…Industrial platinum on graphite catalysts, prepared by salt deposition from aqueous solution, have been examined using transmission electron microscopy. …”

Anatomically conformable, three-dimensional, detachable platinum microcoil system for the treatment of intracranial aneurysms. by Niemann, D, Aviv, R, Cowsill, C, Sneade, M, Molyneux, A

“… BACKGROUND AND PURPOSE: The configurations of detachable platinum coils have evolved over the last decade. Our objective was to assess the efficacy of the anatomically conformable three-dimensional (ACT) detachable platinum microcoil in the treatment of intracranial aneurysms. …”

Scanning transmission electron microscopy studies of the deposition of size-selected sub-nanometre platinum clusters by Couillard, M, Palmer, R, Nellist, P

“…Size-selected cluster ions containing four atoms of platinum (Pt-4(-)) have been deposited onto graphite at different deposition energies and investigated by high angle annular dark field imaging in a scanning transmission electron microscope. …”

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results by Zweifel, M, Jayson, G, Reed, N, Osborne, R, Hassan, B, Shreeves, G, Poupard, L, Walicke, P, Balkissoon, J, Chaplin, D, Rustin, G

OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer by Nicum, S, Strauss, V, McGregor, N, McNeish, I, Roux, R, Hall, M, Michael, A, Roberts, C

“…Women with platinum resistant ovarian cancer (OC) have limited responses to standard therapy, and clinical trials with novel agents are therefore highly justified. …”

Electrochemical deposition of Pt nanoparticles on diamond substrates by Hu, J, Lu, X, Foord, J, Wang, Q

“…Platinum nanoparticles were deposited on polished smooth, as-grown large grain and small grain diamond substrates by a potentiostatic method. …”

SURFACE MODIFICATION WITH MACROCYCLE-CONTAINING REDOX-ACTIVE POLYMERS - TOWARDS THE DESIGN OF NOVEL SPECTROELECTROCHEMICAL GROUP IA IIA METAL CATION SENSORS by Beer, P, Kocian, O, Mortimer, R, Ridgway, C

“…Such complexes can be electropolymerized onto platinum and optically transparent conducting glass electrodes. …”

Development of a fast-response calorimeter heat transfer gauge for hypersonic ground testing by Geraets, RTP, McGilvray, M, Doherty, LJ, Morgan, RG, James, CM, Vanyai, T, Buttsworth, DR

“…Desirable response time and robustness are achieved by using a 75 µm to 300 µm thick layer of synthetic diamond as the calorimeter and a platinum thin film resistance thermometer to measure the temperature rise. …”

AP-FIM investigation on gamma-based titanium aluminides by Kim, S, Smith, G

“…It was not until recently however, that non-conventional beta-stabilising elements from platinum group metals (PGMs), such as Ru and Pd, have also attracted attention. …”

Research and Development of ZnBO4 (B = W, Mo) Crystal Scintillators for Dark Matter and Double Beta Decay Searching by Dubovik, A, Vostretsov, Y, Grinyov, B, Danevich, F, Kraus, H, Nagornaya, L, Mikhailik, V, Tupitsyna, I

“…The ZnBO 4 (B = W, Mo) crystals were grown from charge in platinum crucibles with high frequency heating, using the Czochraiski method. …”

Oxidation of dilute H-2 and H-2/O-2 mixtures by hydrogenases and Pt by Woolerton, T, Vincent, K

“…U.S.A. 102 (2005) 16951], and this has led us to compare the ability of hydrogenases and platinum to oxidise low levels of H2 and mixtures of H2 and O2. …”

A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line tre... by Talbot, D, Blackhall, F, Kowalski, D, Ramlau, R, Bepler, G, Grossi, F, Lerchenmuller, C, Pinder, M, Mezger, J, Danson, S, Callies, S, Andre, V, Das, M, Lahn, M, Natale, R

“…<b>Methods:</b> Key eligibility criteria: ECOG PS 0-1, stage IIIB/IV NSCLC all histologies, progression after first-line platinum regimen. Patients randomized (N=180) 2:1 to receive DO+LY (LY 750 mg IV loading ×3, Q1W maintenance) or DO alone (75 mg/m2 D1Q3W) until progression/toxicities. …”